+1
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
Stocks in this Quantisnow insightHealth Care
Historical context for BIOA
Across the 21 sessions after earlier BIOA headlines, the stock closed higher 14 times and lower 7 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BIOA | SPY |
|---|---|---|---|
| May 13, 2026 | BTIG Research initiated coverage on BioAge Labs with a new price target | +5.2% | +0.6% |
| May 8, 2026 | BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | +1.0% | +0.8% |
| May 5, 2026 | BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 | +0.4% | +0.8% |
| Apr 21, 2026 | BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | +4.3% | -0.7% |
| Apr 14, 2026 | BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference | +2.3% | +1.2% |
| Mar 27, 2026 | Needham initiated coverage on BioAge Labs with a new price target | -0.6% | -1.7% |
Quantisnow market dataNASDAQ
BIOA
BioAge Labs Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for BIOA
Full BIOA profile on Quantisnow Follow BIOA and get a push notification the moment its next story breaks.